secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001104659-26-029968
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics presents Phase 1b data showing stable MDS-UPDRS and biomarker improvements for GT-02287 at AD/PD 2026
--------------------------------------------------------------------------------

- Phase 1b: 19 completed Part 1, 16 entered extension; DMC approved continuation without changes.
- MDS-UPDRS scores stable over 150 days; high GluSph group showed 6.7-point difference vs low group.
- DDC decreased after 90 days in high GluSph baseline group, supporting disease-modifying potential.
- Preclinical data for novel GCase modulator GT-04686 presented, ready for IND-enabling studies.
- Extension study expected to complete September 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926029968/0001104659-26-029968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926029968/tm269191d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-029968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer